Movers

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) fell sharply in today’s pre-market trading after the company reported the Phase 3 ADVANCE-2 trial evaluating…

Monday, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) released top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for negative symptoms of schizophrenia.  Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26…